Enzo Biochem, Inc.
ENZ was delisted on the 17th of April, 2025.
81 hedge funds and large institutions have $84.8M invested in Enzo Biochem, Inc. in 2019 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 25 increasing their positions, 24 reducing their positions, and 11 closing their positions.
1,800% more call options, than puts
Call options by funds: $19K | Put options by funds: $1K
4% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 24
7% less funds holding
Funds holding: 87 → 81 (-6)
28% less capital invested
Capital invested by funds: $117M → $84.8M (-$32.7M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
55% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Fondren Management
Houston,
Texas
|
+$1.11M |
| 2 |
Renaissance Technologies
New York
|
+$162K |
| 3 |
Morgan Stanley
New York
|
+$140K |
| 4 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$117K |
| 5 |
Millennium Management
New York
|
+$114K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EI
EAM Investors
Solana Beach,
California
|
-$734K |
| 2 |
MCM
Marathon Capital Management
Hunt Valley,
Maryland
|
-$478K |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
-$427K |
| 4 |
DGHMC
Dalton, Greiner, Hartman, Maher & Co
New York
|
-$288K |
| 5 |
AI
Ariel Investments
Chicago,
Illinois
|
-$181K |
ENZ Hedge Fund Activity: Q4 2019 in Review
81 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Enzo Biochem, Inc. (ENZ) for Q4 2019, worth a combined $84.8M — down 28% from $117M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ENZ and 5 opened new positions — a net loss of 6 holders — while 24 trimmed existing stakes and 25 added.
The largest buyer was Fondren Management, adding an estimated $1.11M. The largest seller was EAM Investors, exiting entirely with an estimated $734K sold.
- 81 institutional investors held Enzo Biochem, Inc. (ENZ) as of Q4 2019, down from 87 in Q3 2019.
- Funds reported $84.8M of Enzo Biochem, Inc. stock for Q4 2019, down 28% quarter-over-quarter.
- 5 funds opened new Enzo Biochem, Inc. positions in Q4 2019 and 11 closed out, a net change of -6 holders.
- The largest Enzo Biochem, Inc. buyer in Q4 2019 was Fondren Management, an estimated $1.11M added.
- The largest Enzo Biochem, Inc. seller in Q4 2019 was EAM Investors, an estimated $734K sold.
Based on aggregated 13F filings for Q4 2019.